ReviewVaccine: X2020

Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.

Thomas P Monath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.